Clinically, in the KRYSTAL-7 trial, the combination of the KRAS G12C inhibitor adagrasib with the ICI pembrolizumab demonstrated an ORR of 49% and a DCR of 89% in patients with KRAS G12C–mutated advanced non–small cell lung cancer.47 The gene discussed is KRAS; the disease is lung cancer.